Interna Therapeutics is an innovative biotechnology company that developed a transformational delivery technology for macromolecules.
The pioneering technology, named Molecular Nano-Motors (MNMs), is based on a novel mechanism that leverages membrane electrical forces, facilitating entry of charged molecules into cells.
With this technology new treatment options become available for a wide range of diseases using difficult to deliver molecules such as oligonucleotide-based drugs (siRNA, ASO).
Equipped with full-capacity research facilities and working with leading research organizations, the team of seasoned scientists has demonstrated the therapeutic potential of MNM technology in numerous preclinical studies, with a Phase I study of a COVID-19 drug that began in September 2024.
Interna’s innovative spirit and scientific excellence has been recognized by key opinion leaders in the pharma industry and by non-governmental organizations.
Company Details
- Employees
- 19
- Address
- 5-7 Odem St., Petah Tikva,israel
- Industry
- Biotechnology
- Website
- https://interna.bio/
- HQ
- Petah Tikva
Interna Therapeutics Questions
Interna Therapeutics's website is https://interna.bio/
Interna Therapeutics's LinkedIn profile is https://il.linkedin.com/company/internatherapeutics
Interna Therapeutics has
19 employees.
View email and phone details for 19
employees at Interna Therapeutics.
Interna Therapeutics's industry is
Biotechnology
Interna Therapeutics's top competitors are
Tikcro Technologies,
Eitan Medical,
Neurim Pharmaceuticals Ltd,
Neotx Therapeutics Ltd,
Chemomab Therapeutics,
Futuragene Ltd.,
Centarix,
Betalin Therapeutics Ltd.,
Prilenia,
Tsofun.
Interna Therapeutics's categories are Biotechnology
